TABLE 3

Main clinical characteristics of the patients with MODY5 due to mutations or deletions of TCF2

MutationDeletionP
n1810
Age at latest follow-up (years)45.7 ± 11.6 (34–73)37.5 ± 15 (13–57)NS
Age at first manifestation (years)27.7 ± 13.9 (1–58)17.8 ± 14.8 (1–52)0.04
Diabetes
    Age at diagnosis (years)29.5 ± 12.2 (10–58)25.7 ± 15 (10–53)NS
    Symptoms at diagnosis (yes/no)4/147/30.02
    BMI at diagnosis (kg/m2)24.9 ± 3.3 (17.8–32)21.6 ± 4.0 (15–26.9)NS
    HbA1c at last examination (%)7.2 ± 1.0 (5.6–9.2)7.1 ± 1.6 (5.5–9.5)NS
    Insulin therapy (yes/no)14/46/4NS
Kidney disease
    Age at diagnosis (years)32.4 ± 16.2 (1–63)22.7 ± 17.2 (1–57)NS
    Kidney cysts (yes/no)14/47/3NS
    Other kidney morphological abnormalities8/106/4NS
    Creatinine clearance at latest examination (ml/min of 1.73 m2)40 ± 20.1 (5.5–74)61.0 ± 31.6 (15.8–108)NS
    Systolic blood pressure (mmHg)127 ± 18 (104–170)127 ± 15 (106–150)NS
    Diastolic blood pressure (mmHg)76 ± 8 (60–90)73 ± 6 (60–80)NS
Genital abnormalities
    n/n examined8/104/5NS
Pancreas morphology abnormalities
    n/n examined9/153/5NS
Liver disease
    Liver tests abnormalities (yes/no)14/39/1NS
  • Data are means ± SD (range).